Treatment of skin oncological disease using an immusupressive medication

Abstract

Introduction: Skin cancer or non-melanoma malignant formations, as well as melanomas, are recorded in more than 2-3 million people every year. The most important cause of the occurrence of this disease is the effect of UV radiation on damaged areas of the skin, birthmarks, or sensitive skin (light, capable of burning). Dermatoscopy is one of the most important methods for determining the stage of tumor development, and the simplest method of treatment in the initial stages is the use of immunosuppressive agents that reduce the work of the immune system by preventing the formation of antibodies.Objectives: The study aims to investigate the correlation between immunosuppressive drug usage and susceptibility to skin oncological diseases. The study investigated the correlation between immunosuppressive drug usage and susceptibility to skin cancer, particularly melanoma. The specific objectives involve assessing the influence of these medications on melanoma risk, understanding their effects on skin cancer treatment outcomes, optimizing treatment approaches for reduced adverse effects, uncovering the intricate interplay between immune suppression and cancer management, contextualizing findings within the framework of cancer immunotherapy advancements, and revealing the impact of immunosuppressive drugs on susceptibility to rare cancers like Kaposi’s sarcoma. Methods: For this study, it was taken a case of Kaposi’s sarcoma from an 82-year-old man. The patient took 122 doses of the immunosuppressive drug Nivolumab for 2 weeks. Results: After the end of the drug’s intake, the parts of the gastrointestinal tract were examined, and as a result, it was found that the patient recovered. When compared with people who do not take immunosuppressive drugs, there is a high risk of melanoma development; moreover, the highest risk has been found in drugs used to prevent the rejection of transplanted organs. The negative effects of immunosuppressive drugs such as immunosuppression and skin photosensitivity may explain these results. These findings may help reduce the risk of skin oncological disease through increased surveillance and awareness and more careful sun exposure for doctors and users of these drugs